Please use this identifier to cite or link to this item:
http://nopr.niscpr.res.in/handle/123456789/66473| metadata.dc.identifier.doi: | https://doi.org/10.56042/ijbb.v62i10.20912 |
| Title: | Computational insights into Curcumin's modulation of Epithelial-mesenchymal transition in pulmonary fibrosis |
| Authors: | Shivangi, Km Muyal, Jai Prakash Mishra, Amaresh |
| Keywords: | In silico;Molecular docking;Preclinical validation;Protein-protein interaction;SwissADME;Toxicity prediction |
| Issue Date: | Oct-2025 |
| Publisher: | NIScPR-CSIR, India |
| Abstract: | Pulmonary fibrosis (PF) is a progressive interstitial lung disease characterized by excessive production and accumulation of extracellular matrix, resulting in permanent lung damage. The epithelial-mesenchymal transition (EMT) plays a central part in the development of fibrosis; however, therapeutic strategies targeting EMT remain limited. Curcumin, a natural polyphenol with known anti-inflammatory and anti-fibrotic properties, presents a promising candidate for modulating EMT. This study aimed to evaluate the potential of curcumin as an EMT-targeting agent in pulmonary fibrosis using computational approaches. Protein targets of curcumin were predicted using the SwissTargetPrediction and STITCH databases. Protein-protein interaction (PPI) networks were analysed via STRING. Molecular docking studies were performed using AutoDock Vina with EMT-related proteins (TGFBR1, EGFR, MAPK1, and MMP9). Drug-like and pharmacokinetic properties were assessed using SwissADME, while toxicity was evaluated through Protox-II. Curcumin demonstrated strong binding affinity for multiple EMT regulators, suggesting potential inhibitory activity. Network analysis revealed dense interconnectivity among curcumin targets, indicating a co-regulated EMT-related functional cluster. Curcumin also exhibited favourable drug-like parameters and a low predicted toxicity profile (LD50: 2000 mg/kg). This study supports the role of curcumin as a multitarget modulator of epithelial-mesenchymal transition (EMT) with therapeutic relevance in pulmonary fibrosis. The results warrant further experimental validation to confirm its efficacy and safety in preclinical models. |
| Page(s): | 1111-1117 |
| ISSN: | 0975-0959 (Online);0301-1208 (Print) |
| Appears in Collections: | IJBB Vol.62(10) [October 2025] |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| IJBB 62(10) 1111-1117.pdf | 1.24 MB | Adobe PDF | View/Open |
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.